Evidence map›Paper›PMID 33987683›Full record

ArticleAnnals of hematology2021

Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.

Bernard Regidor, Marissa-Skye Goldwater, Jessica Wang, Sean Bujarski, Regina Swift, Benjamin Eades, Marsiye Emamy-Sadr, Shahrooz Eshagian, Gary Schwartz, Tanya M Spektor and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06115135 (A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06115135 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)

TypeinterventionalSponsorOncotherapeuticsRan2024 to 2027Enrolled39ConditionsMultiple Myeloma in Relapse, Multiple Myeloma, RefractoryArmsVenetoclax
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Bernard RegidorJames R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA.
Marissa-Skye GoldwaterJames R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA.
Jessica WangJames R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA.
Sean BujarskiJames R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA.
Regina SwiftJames R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA.
Benjamin EadesJames R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA.
Marsiye Emamy-SadrJames R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA.
Shahrooz EshagianCedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Gary SchwartzJames R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA.
Tanya M SpektorOncotherapeutics, West Hollywood, CA, 90069, USA.
James R BerensonJames R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA. jberenson@imbcr.org.
Oncotherapeutics (United States) · USCedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venetoclax is a BCL-2 inhibitor currently indicated for use in treating hematologic malignancies with recommended doses ranging from 400 to 600 mg/day. Although currently not FDA-approved to treat multiple myeloma (MM) patients, there is a growing number of reports indicating its efficacy as a salvage therapy for these patients, especially for those with the t(11;14) chromosomal marker. These studies, however, have also indicated that venetoclax given at doses ≥ 400 mg/day can cause serious adverse events (SAEs) especially when administered with bortezomib, commonly related to infections. The purpose of this single-center retrospective study was to determine the efficacy of low dose venetoclax (defined as ≤ 250 mg/day) in combination with low dose bortezomib (defined as 1.0 mg/m

Indexed as

AgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBortezomibBridged Bicyclo Compounds, HeterocyclicDexamethasoneFemaleHumansMaleMiddle AgedMultiple MyelomaNeoplasm Recurrence, LocalRetrospective StudiesSulfonamidesTreatment OutcomeAntibodies, MonoclonalBortezomibBridged Bicyclo Compounds, HeterocyclicdaratumumabDexamethasoneSulfonamidesvenetoclaxBortezomibDaratumumabMultiple myelomaVenetoclax

Identifiers

PMID33987683
OpenAlexW3160853206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.